近日,远大医药传出好消息,其放射性产品钇[90Y]微球注射液正式获得美国食品药品监督管理局(FDA)批准新增适应症,用于治疗不可切除肝细胞癌(HCC),成为全球首个且唯一获FDA批准用于不可切除肝细胞癌和结直肠癌肝转移双重适应症的选择性内放射治疗产品。本土化生产降低患者用药成本远大医药在成都的核药研发及生产基地,坐落于温江区成都医学城。全玻璃幕墙的综合研发楼上,远大医药的企业标识格外醒目。这栋崭新...
Source Link近日,远大医药传出好消息,其放射性产品钇[90Y]微球注射液正式获得美国食品药品监督管理局(FDA)批准新增适应症,用于治疗不可切除肝细胞癌(HCC),成为全球首个且唯一获FDA批准用于不可切除肝细胞癌和结直肠癌肝转移双重适应症的选择性内放射治疗产品。本土化生产降低患者用药成本远大医药在成都的核药研发及生产基地,坐落于温江区成都医学城。全玻璃幕墙的综合研发楼上,远大医药的企业标识格外醒目。这栋崭新...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.